BR0004534A - Composto, composição farmacêutica, agente contendo um composto, e uso de um composto. - Google Patents

Composto, composição farmacêutica, agente contendo um composto, e uso de um composto.

Info

Publication number
BR0004534A
BR0004534A BR0004534-9A BR0004534A BR0004534A BR 0004534 A BR0004534 A BR 0004534A BR 0004534 A BR0004534 A BR 0004534A BR 0004534 A BR0004534 A BR 0004534A
Authority
BR
Brazil
Prior art keywords
group
compound
optionally substituted
pyrrole ring
pharmaceutical composition
Prior art date
Application number
BR0004534-9A
Other languages
English (en)
Inventor
Takaichi Shimozato
Nobuyuki Ohkawa
Tomio Kimura
Kazumasa Aoki
Shigeru Ushiyama
Akira Nakao
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BR0004534A publication Critical patent/BR0004534A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, AGENTE CONTENDO UM COMPOSTO, E, USO DE UM COMPOSTO" Compostos de fórmula (I): [em que: A é um anel pirrol; R^ 1^ é um grupo arila ou heteroarila opcionalmente substituído; R^ 2^ representa um grupo heteroarila contendo nitrogênio opcionalmente substituído; R^ 3^ representa um grupo da fórmula -X-R^ 4^, em que X é uma ligação simples ou um grupo alquileno, alquenileno ou alquinileno opcionalmente substituído, e R^ 4^ é um grupo cicloalquila substituído, um grupo arila substituído, um grupo heterociclila substituído, um grupo heterociclila contendo nitrogênio opcionalmente substituído, um grupo heterarila substituído, um grupo heterarila contendo nitrogênio opcionalmente substituído, ou -NR^ a^R^ b^, em que cada um de R^ a^ e R^ b^ é um átomo de hidrogênio ou um grupo alquila, alquenila, alquinila, aralquila ou alquilsulfonila; DESDE QUE os referidos substituintes R^ 1^ e R^ 3^ sejam ligados aos dois átomos do referido anel pirrol que são adjacentes ao átomo do anel pirrol ao qual o referido substituinte R^ 2^ está ligado] apresentam excelente atividade inibidora contra a produção de citosinas inflamatórias.
BR0004534-9A 1999-07-21 2000-07-21 Composto, composição farmacêutica, agente contendo um composto, e uso de um composto. BR0004534A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20549199 1999-07-21
JP36967899 1999-12-27

Publications (1)

Publication Number Publication Date
BR0004534A true BR0004534A (pt) 2001-02-28

Family

ID=26515088

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0004534-9A BR0004534A (pt) 1999-07-21 2000-07-21 Composto, composição farmacêutica, agente contendo um composto, e uso de um composto.

Country Status (22)

Country Link
EP (2) EP1243589A1 (pt)
KR (2) KR100776958B1 (pt)
CN (1) CN1294129C (pt)
AR (1) AR024904A1 (pt)
AT (1) ATE264319T1 (pt)
AU (1) AU773453B2 (pt)
BR (1) BR0004534A (pt)
CA (1) CA2314373A1 (pt)
DE (1) DE60009804T2 (pt)
DK (1) DK1070711T3 (pt)
ES (1) ES2216826T3 (pt)
HK (2) HK1047587A1 (pt)
HU (1) HUP0002846A2 (pt)
ID (1) ID26611A (pt)
IL (1) IL137365A0 (pt)
MX (1) MXPA00007199A (pt)
NO (1) NO20003734L (pt)
NZ (1) NZ505924A (pt)
PL (1) PL341620A1 (pt)
PT (1) PT1070711E (pt)
TR (1) TR200002120A2 (pt)
TW (1) TWI259834B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
EP1352906A4 (en) * 2001-01-18 2004-06-16 Sankyo Co COMPOSITIONS FOR PREVENTION OR TREATMENT OF LIVER DISEASES
WO2002057255A1 (fr) * 2001-01-22 2002-07-25 Sankyo Company, Limited Derives du pyrrole substitues en 4 ou 5
ATE377598T1 (de) * 2001-01-22 2007-11-15 Sankyo Co Durch bicyclische aminogruppen substituierte verbindungen
EG23054A (en) * 2001-01-22 2004-02-29 Sankyo Co Pyrrole derivatives their preparation and their therapeutic uses
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
WO2002080974A1 (fr) * 2001-04-04 2002-10-17 Sankyo Company, Limited Utilisation medicale d'inhibiteur de production de cytokine
WO2002094267A1 (fr) * 2001-05-24 2002-11-28 Sankyo Company, Limited Preparation pharmaceutique pour prevenir ou traiter l'arthrite
WO2003015781A1 (fr) * 2001-08-15 2003-02-27 Sankyo Company, Limited Nouvelles compositions pharmaceutiques antidiabetiques
EP1541571A4 (en) * 2002-07-19 2008-12-03 Sankyo Co BICYCLIC, UNSATURATED TERTIARY AMINE COMPOUND
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
CA2850551A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5792778A (en) * 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
JP3294616B2 (ja) * 1995-08-10 2002-06-24 メルク エンド カンパニー インコーポレーテッド ２−置換アリールピロール、このような化合物を含む組成物及び使用方法

Also Published As

Publication number Publication date
MXPA00007199A (es) 2003-03-12
PT1070711E (pt) 2004-06-30
AU773453B2 (en) 2004-05-27
AU4875500A (en) 2001-02-01
NO20003734L (no) 2001-01-22
KR20070026708A (ko) 2007-03-08
ID26611A (id) 2001-01-25
CN1294129C (zh) 2007-01-10
HUP0002846A2 (hu) 2002-07-29
HK1047587A1 (zh) 2003-02-28
ATE264319T1 (de) 2004-04-15
HK1033671A1 (en) 2001-09-14
CN1295069A (zh) 2001-05-16
KR100776958B1 (ko) 2007-11-27
ES2216826T3 (es) 2004-11-01
CA2314373A1 (en) 2001-01-21
TR200002120A3 (tr) 2001-06-21
KR20010049843A (ko) 2001-06-15
TR200002120A2 (tr) 2001-06-21
AR024904A1 (es) 2002-10-30
IL137365A0 (en) 2001-07-24
EP1070711A2 (en) 2001-01-24
DE60009804D1 (de) 2004-05-19
EP1070711B1 (en) 2004-04-14
NO20003734D0 (no) 2000-07-20
EP1070711A3 (en) 2001-01-31
EP1243589A1 (en) 2002-09-25
HU0002846D0 (en) 2000-09-28
DK1070711T3 (da) 2004-05-10
TWI259834B (en) 2006-08-11
PL341620A1 (en) 2001-01-29
NZ505924A (en) 2001-11-30
DE60009804T2 (de) 2005-01-05

Similar Documents

Publication Publication Date Title
BR0004534A (pt) Composto, composição farmacêutica, agente contendo um composto, e uso de um composto.
BR9908764A (pt) Composto e seus sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in vivo, uso destes, processo para prepará-los, e, composição farmacêutica
TR199901578T2 (xx) Klaritromisin form 0 kristali
BR0111754A (pt) Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
NO995846D0 (no) Oksazolidinon-antibakterielle midler med en tiokarbonylfunksjonalitet
PT1200412E (pt) Agentes anti-proliferativos de imidazole
BR0014136A (pt) Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR0207809A (pt) Compostos heteroarila contendo nitrogênio possuindo atividade inibidora contra integrase de hiv
CA2011346A1 (en) 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
ATE297203T1 (de) Antithrombotische mitteln
HUP0004333A2 (hu) Új triazolo [4,5-d] pirimidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE306261T1 (de) Antithrombosemittel
BR0010520A (pt) Novos compostos farmaceuticamente ativos
ATE177420T1 (de) Cyclobutan-derivate als inhibitoren der squalen- synthetase und der protein-farnesyltransferase
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
BR0208338A (pt) Derivados de piridina
BR9706792A (pt) Derivado de tiazol
BR0012610A (pt) Novo derivado de difenilpiperidina
BR0112521A (pt) Indolquinazolinonas
BR0309748A (pt) Derivados de n-acil piperidina e composição compreendendo os mesmos
BR9712221A (pt) Uso de pelo menos um 1,3-bis(n-lactamil) propano, composto, e, composições farmacêutica e cosmética.
BR0208566A (pt) Derivados de beta-carbolina
HUP9800817A2 (hu) Halogén-alk(en)oxi-szubsztituenseket tartalmazó szulfonil-amino-karbonil-triazolinon-származékok, intermedierjeik, előállításuk és alkalmazásuk, hatóanyagként ezeket a vegyületeket tartalmazó herbicid vagy fungicid készítmények
KR960017649A (ko) 아미노사이클로펜탄 유도체

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.